Eli Lilly and Company announced this week that it has secured a 227‑acre parcel in Goochland County, Virginia, for $38.39 million, a move that paves the way for a $5 billion manufacturing complex dedicated to cancer and autoimmune disease therapeutics.
The new site will house a state‑of‑the‑art production line for bioconjugate molecules and monoclonal antibodies, technologies that have become central to modern precision medicine.
State officials project that the facility will generate roughly 650 permanent jobs, a substantial boost for the local labor market and a signal of confidence in Virginia’s skilled workforce.
The land, once a soccer complex operated by Richmond United, has been cleared and prepared for industrial use, underscoring the repurposing of underutilized suburban spaces for high‑tech manufacturing.
The Virginia State Corporation Commission has endorsed a transmission‑line corridor that will supply the plant with the electric power it needs, a project estimated at $98 million, with $87 million earmarked for the line itself.
Construction is slated to break ground in the summer of 2027, with completion targeted for 2028, a timeline that aligns with the company’s broader $50 billion investment plan across the Commonwealth.
Governor Glenn Youngkin praised the investment as a “transformational opportunity” for the state, while Eli Lilly chief executive David Ricks highlighted the facility’s role in expanding the company’s biologics portfolio.
A catalyst for regional growth
Local economic development agencies say the plant will act as a catalyst, encouraging the growth of supplier networks and fostering partnerships with nearby universities that specialize in biomedical research.
Infrastructure to power innovation
The approved transmission line not only supports the Lilly complex but also upgrades the regional grid, delivering reliability that benefits existing industries and future high‑tech ventures alike.
Together, these developments illustrate how strategic land use, public‑private collaboration, and targeted infrastructure can converge to create a thriving biotech corridor in the heart of Virginia.